Projects per year
I am an academic clinical oncologist with a passion for the treatment of patients with Prostate cancer. I am driven by a desire to improve outcomes from all aspects of this disease and to develop new treatments in particular in the fields of External Beam Radiation Therapy, and Bone-seeking radionuclide therapy (also known as Molecular Radiotherapy).
I believe that by leading a clinical trial programme in prostate cancer that I can fulfill these ambitions. In my time in Belfast I have lead the development of a team of dediciated researchers who are all committed to excellence in patient care. Through over 30 clinical trials in the past 17 years I believe that I have helped a significant number of patients and their families cope with this often devastating illness.
In collaboration with 2 other QUB academic oncologists, Professor Suneil Jain and Dr. Aidan Cole, and supported by our NHS colleague Dr. Darren Mitchell we run an academic prostate cancer service embedded in the NHS at the Northern Ireland Cancer Centre, Belfast. This service oversees the treatment and follow-up of thousands of Northern Ireland men diagnosed with prostate cancer with a clinical trial focus. We are supported by an amzing team of research radiographers, physicists, and nurses. In 2016 we were awarded the accoloade of Movember Centre of Excellence for Prostate Cancer Research through our FASTMAN programme of researc hin copllaboration with the University of Manchseter.
In 2014 I was honoured to appointed as Clinical Director of Oncology at the Belfast Trust, a role I proudly served for 3 years. I have also been a Trustee of the Friends of teh Cancer Centre, a local charity helping cancer patienst and their families.
As well as academic leadership, I believe clinical academics have a major contribution to make to the health service. During the past 14 years I have been appointed to a number of key leadership positions within the NHS Trust in Belfast. These roles have allowed me to advocate for the research and quality agenda and I have maintained a focus on excellence iin patient care.
I was clinical lead for radiotherapy from 2008 to 2014 during which time I led the introduction of a number of new treatment techniques and modalities including Intensity Modulated Radiotherapy (IMRT), Image Guided radiotherapy using gold fiducial markers (IGRT), bone-seeking radionuclide therapy, and radiotherapy imaging protocols. I have encouraged the other members of the multi-professional team to think in innovative and progressive ways and this has resulted in a change in culture which is gradually evolving in Belfast.
From 2014-2017, I was Clinical Director of Oncology at Belfast Trust. Through this role I endevoured to increse the profile of clincal research in the cancer service.
I lead the radiation oncology and prostate cancer clinical research groups at the Northern Ireland Cancer Centre, Belfast, and am currently principal investigator on more than 10 clinical trials. I trained in radiation oncology at St. Luke's Hospital, Dublin and subsequently completed a research fellowship at the Academic Urology Unit of The Royal Marsden Hospital. My research interests include bone-seeking radionuclide therapy, image guided radiotherapy, Irradiation of the retina for Macular Degeneration and translational research in radiation and prostate cancer and have published widely in these areas. I collaborate closely with scientists at the CCRCB in particular Prof Kevin Prise and clinical colleagues, in particular Professor Suneil Jain, as well as international colleagues.
I am one of the 4 co-Directors of the Movember Centre of Excellence in Prostate cancer programme grant. The programme is a collaboration with the Christie Hospital Manchester. Known as FASTMAN, the programme is focussed on enhancing the role of radiation in prostate cancer.
My main teaching focus is with the 4th year medicine oncology module.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
05/03/2018 → …
01/08/2010 → …
01/08/2009 → …
R2580PMY: Characteristics of the damage generated by the presence of gold nanoparticles in irridated cells <PHARM/BIOME/MATHS>
01/08/2007 → …
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolSystemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, 28 Jan 2022, In: Lancet (London, England). 399, 10323, p. 447-460
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile29 Downloads (Pure)
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)James, N. D., Clarke, N. W., Cook, A., Ali, A., Hoyle, A. P., Attard, G., Brawley, C. D., Chowdhury, S., Cross, W. R., Dearnaley, D. P., Bono, J. S., Montana, C. D., Gilbert, D., Gillessen, S., Gilson, C., Jones, R. J., Langley, R. E., Malik, Z. I., Matheson, D. J., Millman, R. & 36 others, , 12 Apr 2022, (Early online date) In: International Journal of Cancer.
Research output: Contribution to journal › Article › peer-review
Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastropheGuerra Liberal, F. D. C., Moreira, H., Redmond, K. M., O'Sullivan, J. M., Alshehri, A. H. D., Wright, T. C., Dunne, V. L., Campfield, C., Biggart, S., McMahon, S. J. & Prise, K. M., 28 Jul 2022, In: Frontiers in oncology. 12, 877302.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile20 Downloads (Pure)
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialJames, N. D., Ingleby, F. C., Clarke, N. W., Amos, C. L., Attard, G., Brawley, C. D., Chowdhury, S., Cross, W., Dearnaley, D. P., Gilbert, D. C., Gillessen, S., Jones, R. J., Langley, R. E., Macnair, A., Malik, Z. I., Mason, M. D., Matheson, D. J., Millman, R., Parker, C. C., Rush, H. L. & 27 others, , Aug 2022, In: JNCI Cancer Spectrum. 6, 4, pkac043.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile7 Downloads (Pure)
Bastiani, I., McMahon, S. J., Turner, P., Redmond, K. M., McGarry, C. K., Cole, A., O'Sullivan, J. M., Prise, K. M., Ainsbury, L. & Anderson, R., 01 Mar 2022, In: Nuclear Medicine and Biology. 106-107, p. 10-20 11 p.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile31 Downloads (Pure)
Prize: Prize (including medals and awards)
Prize: Prize (including medals and awards)
Philip Dunne (Host), Donna Small (Recipient), Stephanie Craig (Recipient), Simon McDade (Recipient), Sudhir Malla (Recipient), Raheleh Amirkhah (Recipient), Yaser Atlasi (Recipient), Joe O'Sullivan (Recipient) & James Boncan (Recipient)2022 → …
Activity: Other activity types › Other